Effective reimbursements in expanding homecare sector to boost enteral feeds

16 January 2006

Strict reimbursement regulations across the European health care spectrum are likely to have a detrimental effect on the uptake of enteral feeds by hospitals, according to consultant Frost & Sullivan. However, the establishment of effective reimbursement, particularly within the rapidly expanding home-care sector, is set to boost adoption levels of enteral feed products.

Reimbursement regulations, such as the legislation effected in Germany in October 2005, have reduced the disease/patient conditions that are entitled to receive enteral nutrition on a reimbursable basis (27 disease conditions reduced to four). As a consequence, the hospital business as well as investments and innovations in this area by manufacturers are being negatively affected, notes F&S.

However, the rising importance of the home-care segment bodes well for eternal feed manufacturers. Due to persistent cost pressures in the hospital segment, there has been a shift from extended hospital treatment towards treatment at home, the consultant points out. Also, growing awareness of the importance of therapeutic nutrition has contributed to patients increasingly using enteral nutrition products at home.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight